Dietary intakes and biomarker patterns of folate, vitamin B6, and vitamin B12 can be associated with cognitive impairment by hypermethylation of redox-related genes NUDT15 and TXNRD1.

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a clinical trial.

EMCOA, ChiCTR-OOC-17011882, Registered 5th, July 2017-Retrospectively registered, http://www.medresman.org/uc/project/projectedit.aspx?proj=2610.

Who Took Part

According to the abstract, 2533 participants were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Participants were selected from a large cohort study entitled the Effects and Mechanism Investigation of Cholesterol and Oxysterol on Alzheimer's disease (EMCOA) study.

The researchers included 2533 participants who completed a selection of comprehensive cognitive tests and a semiquantitative food frequency questionnaire (FFQ) and were followed for an average of 2.3 years.

How the Study Was Run

The longitudinal effects of B vitamin intake on cognitive decline were examined using linear mixed-effect models.

Seven mild cognitive impairment (MCI) patients, in the predementia stage of Alzheimer's disease (AD), and fivev healthy controls were selected for the discovery of genome-wide differentially methylated CpG sites.

The correlations between DNA methylation levels and serum concentrations of B vitamins and oxidative biomarkers were analyzed with Spearman's correlation.

The interactive effects of DNA methylation and B vitamins on cognitive performance were further evaluated by multiple linear regression.

What Was Measured

Topics PubMed links to this paper include Alzheimer Disease, Case-Control Studies, Cognitive Dysfunction, DNA Methylation, Dietary Supplements, Epigenesis, Genetic and Folic Acid.

The authors tagged it with the keywords Cognitive impairment, Folate, Oxidative stress and Vitamin B12.

What This Means in Plain Language

This is a clinical trial of Cyanocobalamin (Vitamin B12) in 2533 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Clinical epigenetics), a journal based in Germany.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.